<DOC>
	<DOCNO>NCT01562899</DOCNO>
	<brief_summary>This multi-center , open-label , phase Ib/II study . First , aim phase Ib part estimate MTD ( ) and/or identify recommended phase II dose ( ) ( RP2D ) combination MEK162 AMG 479 ( ganitumab ) , follow phase II part ass clinical efficacy assess safety combination select patient population . The dose escalation part study guide Bayesian Logistic Regression Model ( BLRM ) . At least 18 patient expect enrol dose escalation part . Following MTD/ RP2D declaration , patient enrol three phase II arm ass efficacy combination well well understand safety , tolerability , PK , antibody concentration PD combination MTD/RP2D . Phase II arm 1 consist approximately 25 patient KRAS-mutant colorectal adenocarcinoma . Phase II arm 2 consist approximately 20 patient metastatic pancreatic adenocarcinoma . Phase II arm 3 consist approximately 28 patient mutant BRAFV600 melanoma . Patients treated progression disease , unacceptable toxicity develop , withdrawal informed consent , whichever occur first . All patient follow - minimum patient must complete safety follow-up assessment 30 day last dose study treatment .</brief_summary>
	<brief_title>A Study MEK162 AMG 479 Patients With Selected Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients age ≥ 18 year Patients advance solid tumor ( CRC , melanoma ) document somatic KRAS BRAFV600 mutation tumor tissue . Patients metastatic pancreatic adenocarcinoma may enrol irrespectively KRAS BRAFV600 mutational status . Patients must relapse progress follow standard therapy patient standard anticancer therapy exists . Measurable disease determine RECIST v1.1 . World Health Organization ( WHO ) Performance Status ( PS ) ≤ 2 . Adequate organ function Negative serum pregnancy test Prior therapy MEK IGF1R inhibitor History current evidence central serous retinopathy ( CSR ) , retinal vein occlusion ( RVO ) retinal degenerative disease Patients known history severe infusion reaction monoclonal antibody Patients primary CNS tumor CNS tumor involvement History thromboembolic event require fulldose anticoagulation therapy Clinically significant cardiac disease History another malignancy within 2 year Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEK162</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Ganitumab</keyword>
	<keyword>colorectal adenocarcinoma</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
</DOC>